AKR1C3 and acute myeloid leukemia: (3) Aldo-keto reductase family 1 member C3 (AKR1C3) [27]: In AML and T-cell acute lymphoblastic leukemia (T-ALL), AKR1C3 expression in the tumor cell cytoplasm degrades doxorubicin hydrochloride, causing treatment resistance.